Literature DB >> 16306804

Cardioprotection with adenosine A2 receptor activation at reperfusion.

Zhelong Xu1, Robert A Mueller, Sung-Sik Park, Philip G Boysen, Michael V Cohen, James M Downey.   

Abstract

Pre-ischemic treatment is seldom possible in the clinical setting of acute myocardial infarction. Thus, to successfully save myocardium from infarction, it is required that protective interventions must be effective when applied after ischemia has begun or at the onset of reperfusion. Unfortunately, in spite of a large body of experimental data showing that various interventions are cardioprotective at reperfusion, no specific therapy has yet been established to be clinically applicable. However, recent data from several laboratories have shown that adenosine and its analogues given at reperfusion can markedly protect the heart from ischemia/reperfusion injury. While the experimental data suggest that factors such as adenosine A2 receptor activation, anti-neutrophil effect, attenuation of free radical generation, increased nitric oxide (NO) availability, activation of the PI3-kinase/Akt pathway and ERK, prevention of mitochondrial damage, and anti-apoptotic effects may be involved in the protective effect of adenosine or its analogues, the exact receptor subtype(s), the detailed signaling mechanisms, and interaction between those individual factors are still unknown. A definite answer to these unsolved problems will offer insights into the mechanisms of cardioprotection at reperfusion, and will be critical for developing a successful therapeutic strategy to salvage ischemic myocardium in patients with acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306804     DOI: 10.1097/01.fjc.0000188161.57018.29

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Beyond anoxia: the physiology of metabolic downregulation and recovery in the anoxia-tolerant turtle.

Authors:  Sarah L Milton; Howard M Prentice
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2006-09-05       Impact factor: 2.320

2.  Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts.

Authors:  Carmen Methner; Katharina Schmidt; Michael V Cohen; James M Downey; Thomas Krieg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-13       Impact factor: 4.733

3.  Variants of the adenosine A(2A) receptor gene are protective against proliferative diabetic retinopathy in patients with type 1 diabetes.

Authors:  Bashira A Charles; Yvette P Conley; Guanjie Chen; Rachel G Miller; Janice S Dorman; Michael B Gorin; Robert E Ferrell; Susan M Sereika; Charles N Rotimi; Trevor J Orchard
Journal:  Ophthalmic Res       Date:  2010-11-19       Impact factor: 2.892

4.  Evidence for an intracellular localization of the adenosine A2B receptor in rat cardiomyocytes.

Authors:  Karina Grube; Julia Rüdebusch; Zhelong Xu; Thomas Böckenholt; Carmen Methner; Tobias Müller; Friederike Cuello; Katrin Zimmermann; Xiulan Yang; Stephan B Felix; Michael V Cohen; James M Downey; Thomas Krieg
Journal:  Basic Res Cardiol       Date:  2011-01-19       Impact factor: 17.165

5.  Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages.

Authors:  Allison B Reiss; Steven E Carsons; Kamran Anwar; Soumya Rao; Sari D Edelman; Hongwei Zhang; Patricia Fernandez; Bruce N Cronstein; Edwin S L Chan
Journal:  Arthritis Rheum       Date:  2008-12

6.  The reno-vascular A2B adenosine receptor protects the kidney from ischemia.

Authors:  Almut Grenz; Hartmut Osswald; Tobias Eckle; Dan Yang; Hua Zhang; Zung Vu Tran; Karin Klingel; Katya Ravid; Holger K Eltzschig
Journal:  PLoS Med       Date:  2008-06-24       Impact factor: 11.069

7.  Hepatic cell mobilization for protection against ischemic myocardial injury.

Authors:  Shu Q Liu; John B Troy; Chi-Hao Luan; Roger J Guillory
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.